GLA
ALXN

Great Lakes Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Great Lakes Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,954
Closed -$968K – 604
2019
Q4 		$968K Buy
+8,954
New +$958K 0.02% 390
2017
Q4 		– Sell
-16,557
Closed -$2.32M – 627
2017
Q3 		$2.32M Buy
+16,557
New +$2.25M 0.05% 277
2014
Q1 		– Sell
-25
Closed -$3K – 399
2013
Q4 		$3K Buy
+25
New +$3K ﹤0.01% 346

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Great Lakes Advisors's ALXN Position: Q1 2020 in Review

Great Lakes Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 8,954 shares — an estimated $968K sold.

Great Lakes Advisors first reported a position in ALXN in Q4 2013 and held it in 3 quarters. The position peaked at $2.32M in Q3 2017. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Great Lakes Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Great Lakes Advisors sold 8,954 Alexion Pharmaceuticals shares in Q1 2020, an estimated $968K.
  • Great Lakes Advisors first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Great Lakes Advisors's Alexion Pharmaceuticals position peaked at $2.32M in Q3 2017.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Great Lakes Advisors's 13F filing for Q1 2020, filed 8 May 2020.